{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus-diphtheria-acellular+pertussis+%28Tdap%29+vaccine",
    "query": {
      "intervention": "Tetanus-diphtheria-acellular pertussis (Tdap) vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 46,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus-diphtheria-acellular+pertussis+%28Tdap%29+vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T11:14:25.824Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04766086",
      "title": "Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Group B Streptococcus Infections"
      ],
      "interventions": [
        {
          "name": "Multivalent Group B streptococcus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus, diphtheria, and acellular pertussis vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 306,
      "start_date": "2022-08-12",
      "completion_date": "2023-04-27",
      "has_results": true,
      "last_update_posted_date": "2024-05-24",
      "last_synced_at": "2026-10-07T11:14:25.824Z",
      "location_count": 12,
      "location_summary": "Newton, Kansas • Omaha, Nebraska • Las Vegas, Nevada + 8 more",
      "locations": [
        {
          "city": "Newton",
          "state": "Kansas"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04766086"
    },
    {
      "nct_id": "NCT06639074",
      "title": "Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Fallopian Tube Carcinoma",
        "Advanced Fallopian Tube High Grade Serous Adenocarcinoma",
        "Advanced Ovarian Carcinoma",
        "Advanced Ovarian Carcinosarcoma",
        "Advanced Ovarian Clear Cell Adenocarcinoma",
        "Advanced Ovarian Endometrioid Adenocarcinoma",
        "Advanced Ovarian High Grade Serous Adenocarcinoma",
        "Advanced Primary Peritoneal Carcinoma",
        "Advanced Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Fallopian Tube Carcinosarcoma",
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Adenocarcinoma",
        "FIGO Stage III Ovarian Cancer 2014",
        "FIGO Stage IV Ovarian Cancer 2014",
        "Ovarian Mixed Cell Adenocarcinoma",
        "Primary Peritoneal Carcinosarcoma",
        "Primary Peritoneal Clear Cell Adenocarcinoma",
        "Primary Peritoneal Endometrioid Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Tetanus and Diphtheria Toxoids Adsorbed",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 78,
      "start_date": "2024-11-12",
      "completion_date": "2029-04-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-07T11:14:25.824Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06639074"
    },
    {
      "nct_id": "NCT00467519",
      "title": "Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tetanus",
        "Diphtheria",
        "Pertussis"
      ],
      "interventions": [
        {
          "name": "Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "4 Years to 6 Years"
      },
      "enrollment_count": 1045,
      "start_date": "2007-04",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2014-02-07",
      "last_synced_at": "2026-10-07T11:14:25.824Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467519"
    },
    {
      "nct_id": "NCT02543918",
      "title": "A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ixekizumab",
          "type": "DRUG"
        },
        {
          "name": "Boostrix®",
          "type": "DRUG"
        },
        {
          "name": "Pneumovax®23",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 84,
      "start_date": "2015-09",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-01-06",
      "last_synced_at": "2026-10-07T11:14:25.824Z",
      "location_count": 3,
      "location_summary": "Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543918"
    },
    {
      "nct_id": "NCT02518555",
      "title": "Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jennifer Woyach",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2016-01-12",
      "completion_date": "2026-01-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-07T11:14:25.824Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02518555"
    },
    {
      "nct_id": "NCT04006457",
      "title": "Long-Term PF-06651600 for the Treatment of Alopecia Areata",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "PF-06651600",
          "type": "DRUG"
        },
        {
          "name": "Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1057,
      "start_date": "2019-07-18",
      "completion_date": "2026-02-26",
      "has_results": true,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-10-07T11:14:25.824Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Irvine, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04006457"
    },
    {
      "nct_id": "NCT03530124",
      "title": "Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Apnea",
        "Apnea Neonatal",
        "Prematurity"
      ],
      "interventions": [
        {
          "name": "PCV13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HBV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IPV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hib",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Weeks and older"
      },
      "enrollment_count": 223,
      "start_date": "2018-07-17",
      "completion_date": "2021-11-01",
      "has_results": true,
      "last_update_posted_date": "2024-02-14",
      "last_synced_at": "2026-10-07T11:14:25.824Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Chapel Hill, North Carolina • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03530124"
    },
    {
      "nct_id": "NCT00855855",
      "title": "Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Haemophilus Infections",
        "Diphtheria",
        "Tetanus",
        "Polio",
        "Pertussis"
      ],
      "interventions": [
        {
          "name": "DTaP-IPV/Hib",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "Up to 59 Months"
      },
      "enrollment_count": 20830,
      "start_date": "2009-02",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-10-07T11:14:25.824Z",
      "location_count": 59,
      "location_summary": "Albany, California • Martinez, California • San Francisco, California + 56 more",
      "locations": [
        {
          "city": "Albany",
          "state": "California"
        },
        {
          "city": "Martinez",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Applewood",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00855855"
    },
    {
      "nct_id": "NCT02587520",
      "title": "Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Tetanus",
        "Diphtheria",
        "Pertussis",
        "Whooping Cough"
      ],
      "interventions": [
        {
          "name": "Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 1363,
      "start_date": "2015-10-22",
      "completion_date": "2017-02-21",
      "has_results": true,
      "last_update_posted_date": "2022-03-23",
      "last_synced_at": "2026-10-07T11:14:25.824Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02587520"
    },
    {
      "nct_id": "NCT00707148",
      "title": "Pertussis Vaccine in Healthy Pregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diphtheria",
        "Pertussis",
        "Tetanus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "Up to 45 Years"
      },
      "enrollment_count": 80,
      "start_date": "2009-01",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2014-07-25",
      "last_synced_at": "2026-10-07T11:14:25.824Z",
      "location_count": 4,
      "location_summary": "Durham, North Carolina • Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00707148"
    }
  ]
}